Olmesartan Studies Show “No Clear Evidence” Of CV Risk In Diabetes Patients, FDA Finds
This article was originally published in The Pink Sheet Daily
Although data raise “concern of possible increased CV risk” with use of high-dose olmesartan in diabetic patients, FDA concludes that use of the drug in this group can continue.
You may also be interested in...
Given risk of serious gastrointestinal disorder, Public Citizen argues there is no reason to keep the drugs on the market when so many alternative treatments are available
CDER Deputy Director Bob Temple is a confirmed skeptic of the value of observational trial data to FDA’s regulatory decisions. A recent Medicare study on the bleeding risks associated with Boehringer-Ingelheim’s Pradaxa, however, confirmed an earlier position on the drug by FDA and meets with Temple’s approbation.
The nine drug manufacturers with products selected for Medicare drug price negotiations have agreed to participate in the program. Seven of them now have pending suits challenging the Inflation Reduction Act program with Novo’s recent complaint, which objects to the aggregation of its insulin products.